Search - tctmd.com

Displaying 21 - 40 of 96

Sort: Relevancy | Date

Avoiding PVL by Valve design in the Younger Patients

Presentation TVT 2022

Avoiding PVL by Valve design in the Younger Patients

Presenter: Michael Reardon

June 08, 2022

Hemodynamics and the Impact For Younger Patients

Presentation TVT 2022

Hemodynamics and the Impact For Younger Patients

Presenter: Michael Reardon

June 08, 2022

Evidence of Structural Valve Deterioration After TAVI: Recent Echo Findings

Presentation TVT 2022

Evidence of Structural Valve Deterioration After TAVI: Recent Echo Findings

Presenter: Michael J. Reardon

June 08, 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

DurAVR THV: A Novel 3D Single Piece Valve Designed for Improved Durability and Hemodynamics

Presentation TCT 2021

DurAVR THV: A Novel 3D Single Piece Valve Designed for Improved Durability and Hemodynamics

Presenter: Samir Kapadia

November 05, 2021

Illustrative Cases

Presentation TVT 2019

Illustrative Cases

Presenter: Michael Reardon

June 13, 2019

Next Generation TAVR Devices

Presentation SIF 2019

Next Generation TAVR Devices

Presenter: Michael J Reardon

March 30, 2019

Top 4 Structural Trials of the Last Year

Presentation SIF 2019

Top 4 Structural Trials of the Last Year

Presenter: Michael J Reardon

March 27, 2019

Primary Results From the Evolut Low Risk Trial

Presentation ACC 2019

Primary Results From the Evolut Low Risk Trial

Presenter: Michael J. Reardon

March 17, 2019

Intrepid: Device Attributes, Implant Procedure, Clinical Results, and APOLLO Design and Status

Presentation TCT 2018

Intrepid: Device Attributes, Implant Procedure, Clinical Results, and APOLLO Design and Status

Presenter: Michael J. Mack, David W.M. Muller, Michael J. Reardon

September 24, 2018

Secondary Mitral Regurgitation With Severely Reduced LVEF

Presentation TCT 2018

Secondary Mitral Regurgitation With Severely Reduced LVEF

Presenter: Vinayak Bapat, Susheel K. Kodali, Philippe Genereux, Martin B. Leon, Scott Lim, Michael J. Mack, Raj Makkar, Patrick T. O'Gara, Michael J. Reardon, Allan Schwartz

September 23, 2018

Bicuspid Aortic Stenosis: How To Treat

Presentation TCT 2018

Bicuspid Aortic Stenosis: How To Treat

Presenter: Vinayak Bapat, Susheel K. Kodali, Philippe Genereux, Martin B. Leon, Scott Lim, Michael J. Mack, Raj Makkar, Patrick T. O'Gara, Michael J. Reardon, Allan Schwartz

September 23, 2018

Low Surgical Risk Aortic Stenosis In The Us: The Patient Really Wants TAVR

Presentation TCT 2018

Low Surgical Risk Aortic Stenosis In The Us: The Patient Really Wants TAVR

Presenter: Vinayak Bapat, Susheel K. Kodali, Philippe Genereux, Martin B. Leon, Scott Lim, Michael J. Mack, Raj Makkar, Patrick T. O'Gara, Michael J. Reardon, Allan Schwartz

September 23, 2018

Program Update: The LOTUS TAVR System

Presentation TCT 2018

Program Update: The LOTUS TAVR System

Presenter: Michael J. Reardon

September 22, 2018

My Crystal Ball - Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis Once the ‘Cycle' of Low-Risk Studies is Completed

Presentation TCT 2018

My Crystal Ball - Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis Once the Cycle of Low-Risk Studies is Completed

Presenter: Allan Schwartz, Stephan Windecker, Michael J. Reardon

September 22, 2018

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

Presentation TCT 2018

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

Presenter: Charles J. Davidson, Jeffrey J. Popma, Michael J. Reardon

September 21, 2018

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Presentation The Structural Heart Disease Summit 2018

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Presenter: Susheel K. Kodali, Michael J. Reardon, Patrick M. McCarthy

June 21, 2018

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Presentation The Structural Heart Disease Summit 2018

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Presenter: Susheel K. Kodali, Michael J. Reardon, Mathew Williams

June 21, 2018

Once the ‘Cycle' of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

Presentation The Structural Heart Disease Summit 2018

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

Presenter: Allan Schwartz, Stephan Windecker, Michael J. Reardon

June 21, 2018

Case #3: A ‘Small' (Undersized) Surgical Bioprosthesis

Presentation The Structural Heart Disease Summit 2018

Case #3: A Small (Undersized) Surgical Bioprosthesis

Presenter: Michael J. Reardon, Adnan K. Chhatriwalla, Danny Dvir, Ariel Finkelstein, Kendra J. Grubb, Michael J. Mack, Thomas Modine, Mark J. Russo

June 21, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.